{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T15:31:44Z","timestamp":1762875104091},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["International Journal of Hematology"],"published-print":{"date-parts":[[2006,8,1]]},"DOI":"10.1532\/ijh97.06019","type":"journal-article","created":{"date-parts":[[2007,10,18]],"date-time":"2007-10-18T14:05:16Z","timestamp":1192716316000},"page":"158-165","source":"Crossref","is-referenced-by-count":14,"title":["Clinical Evaluation of Recombinant Factor VIII Preparation (Kogenate) in Previously Treated Patients with Hemophilia A: Descriptive Meta-Analysis of Post-Marketing Study Data"],"prefix":"10.1007","volume":"84","author":[{"given":"A.","family":"Yoshioka","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Fukutake","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Takamatsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Shirahata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"E00001","doi-asserted-by":"crossref","unstructured":"Gitschier J, Wood WI, Goralka TM, et al. Characterization of the human factor VIII gene. <i>Nature<\/i>. 1984;312:326-330.","DOI":"10.1038\/312326a0"},{"key":"E00002","doi-asserted-by":"crossref","unstructured":"Wood WI, Capon DJ, Simonsen CC, et al. Expression of active human factor VIII from recombinant DNA clones. <i>Nature<\/i>. 1984;312:330-337.","DOI":"10.1038\/312330a0"},{"key":"E00003","doi-asserted-by":"crossref","unstructured":"Schwartz RS, Abildgaard CF, Aledort LM, et al. Human recombinant DNA-derived antihemophilic factor (factor VIII) in the treatment of hemophilia A: Recombinant Factor VIII Study Group. <i>N Engl J Med<\/i>. 1990;323:1800-1805.","DOI":"10.1056\/NEJM199012273232604"},{"key":"E00004","unstructured":"Yoshioka A. Advances in hemophilia and other coagulation disorders: recombinant factor VIII preparations. <i>Int J Pediatr Hematol Oncol<\/i>. 1994;1:491-497."},{"key":"E00005","unstructured":"Fukui H, Yoshioka A, Shima M, et al. Clinical evaluation of recombinant human factor VIII (BAY w 6240) in the treatment of hemophilia A. <i>Int J Hematol<\/i>. 1991;54:419-427."},{"key":"E00006","unstructured":"Fukui H, Mori K, Ishikawa M, et al. A long-term, multicenter clinical study of recombinant human factor VIII (BAY w 6240) in the treatment of hemophilia A [in Japanese]. <i>Nihon Yuketsu Gakkai Zasshi<\/i>. 1991;37:593-604."},{"key":"E00007","doi-asserted-by":"crossref","unstructured":"Yoshioka A, Fukutake K, Takamatsu J, et al. Clinical evaluation of a recombinant factor VIII preparation (Kogenate) in previously untreated patients with hemophilia A. <i>Int J Hematol<\/i>. 2003;78:467-474.","DOI":"10.1007\/BF02983823"},{"key":"E00008","unstructured":"Kasper CK, Aledort LM, Counts RB, et al. A more uniform measurement of factor VIII inhibitors [letter]. <i>Thromb Diath Haemorrh<\/i>. 1975;34:869-872."},{"key":"E00009","doi-asserted-by":"crossref","unstructured":"Shima M, Sawamoto Y, Nakai H, et al. Measurement of anti-factor VIII IgG,IgG4 and IgM alloantibodies in previously untreated hemophilia A patients treated with recombinant factor VIII: Kogenate Japanese Clinical Study Group. <i>Int J Hematol<\/i>. 1995;62:35-43.","DOI":"10.1016\/0925-5710(95)00378-6"},{"key":"E00010","doi-asserted-by":"crossref","unstructured":"Ehrenforth S, Kruetz W, Scharrer I, et al. Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs. <i>Lancet<\/i>. 1992;339:594-598.","DOI":"10.1016\/0140-6736(92)90874-3"},{"key":"E00011","doi-asserted-by":"crossref","unstructured":"Addiego J, Kasper C, Abildgaard C, et al. Frequency of inhibitor development in haemophiliacs treated with low-purity factor VIII. <i>Lancet<\/i>. 1993;342:462-464.","DOI":"10.1016\/0140-6736(93)91593-B"},{"key":"E00012","doi-asserted-by":"crossref","unstructured":"Ljung R, Petrini P, Lindgren A, et al. Factor VIII and factor IX inhibitor in haemophiliacs. <i>Lancet<\/i>. 1992;339:1550-1551.","DOI":"10.1016\/0140-6736(92)91324-2"},{"key":"E00013","doi-asserted-by":"crossref","unstructured":"deBiasi R, Rocino A, Papa ML, et al. Incidence of factor VIII inhibitor development in hemophilia A patients treated with less pure plasma derived concentrates. <i>Thromb Haemost<\/i>. 1994;71:544-547.","DOI":"10.1055\/s-0038-1642479"},{"key":"E00014","doi-asserted-by":"crossref","unstructured":"Schwartz RS, Abildgaard CF, Aledort LM, et al. Human recombinant DNA-derived antihemophilic factor (factor VIII) in the treatment of haemophilia A. <i>N Engl J Med<\/i>. 1990;323:1800-1805.","DOI":"10.1056\/NEJM199012273232604"},{"key":"E00015","unstructured":"Bray GL, Gomperts ED, Courter S, et al. A multicenter study of recombinant factor VIII (Recombinate): safety, efficacy and inhibitor risk in previously untreated individuals with hemophilia A. <i>Blood<\/i>. 1994;83:2428-2435."},{"key":"E00016","unstructured":"Lusher JM, Spira J, Rodriguez D. A four-year update of safety and efficacy of an albumin-free formulated B-domain deleted factor VIII (BDD rFVIII, rVIIISQ) in previously untreated severe hemophilia A patients. <i>Thromb Haemost<\/i>. 1999;82:1493."},{"key":"E00017","unstructured":"Abe T, Igata A, Ikematsu S, et al. Multicenter clinical effect of heat-treated factor VIII (CP-8) preparation for patients with hemophilia A [in Japanese]. <i>Rinshio to Kenkyu<\/i>. 1985;62:3640-3659."},{"key":"E00018","doi-asserted-by":"crossref","unstructured":"Fujimaki M, Tanaka A, Fukutake K, et al. Clinical evaluation of recombinant factor VIII (BL-160) in patients with hemophilia A [in Japanese]. <i>Nihon Kessen Shiketsu Gakkaishi<\/i>. 1993;4:179-188.","DOI":"10.2491\/jjsth.4.179"},{"key":"E00019","unstructured":"Fujimaki M, Goto M, Miyazaki T, et al. Clinical study of FVIII concentrate highly purified by monoclonal antibodies to FVIII(RCG-11) [in Japanese]. <i>Kiso to Rinsho<\/i>. 1992;26:299-319."},{"key":"E00020","doi-asserted-by":"crossref","unstructured":"McMillan C, Shapiro S, Whitehurst D, et al. The natural history of factor VIII C inhibitors in patients with hemophilia A. A national cooperative study II. Observations on the initial development of factor VIII C inhibitors. <i>Blood<\/i>. 1988;71:344-348.","DOI":"10.1182\/blood.V71.2.344.344"},{"key":"E00021","doi-asserted-by":"crossref","unstructured":"White GC, Courter S, Bray GL, et al. A multicenter study of recombinant factor VIII (RecombinateH) in previously treated patient with hemophilia A. <i>Thromb Haemost<\/i>. 1997;77:660-667.","DOI":"10.1055\/s-0038-1656030"},{"key":"E00022","doi-asserted-by":"crossref","unstructured":"Seremetis S, Lusher JM, Abildgaard CF, et al. Human recombinant DNA-derived antihaemophilic factor (factor VIII) in the treatment of haemophilia A: conclusions of a 5-year study of home therapy. <i>Haemophilia<\/i>. 1999;5:9-16.","DOI":"10.1046\/j.1365-2516.1999.00191.x"},{"key":"E00023","doi-asserted-by":"crossref","unstructured":"Lusher JM, Lee CA, Kessler CM, Bedrosian CL, for the ReFacto Phase 3 Study Group. The safety and efficacy of B-domain deleted recombinant factor VIII concentrate in patients with severe haemophilia A. <i>Haemophilia<\/i>. 2003;9:38-49.","DOI":"10.1046\/j.1365-2516.2003.00708.x"},{"key":"E00024","doi-asserted-by":"crossref","unstructured":"Giles AR, Rivard GE, Teitel J, Walker I. Surveillance for factor VIII inhibitor development in the Canadian hemophilia A population following the widespread introduction of recombinant factor VIII replacement therapy. <i>Transfus Sci<\/i>. 1998;19:139-48.","DOI":"10.1016\/S0955-3886(98)00024-1"},{"key":"E00025","doi-asserted-by":"crossref","unstructured":"Smith MP, Giangrande P, Pollman H, et al. A postmarketing surveillance study of safety and efficacy of Refacto (St. Louis-derived active substance) in patients with haemophilia. <i>Haemophilia<\/i>. 2005;11:444-451.","DOI":"10.1111\/j.1365-2516.2005.01131.x"},{"key":"E00026","doi-asserted-by":"crossref","unstructured":"Rosendaal FR, Nieuwenhuis HK, van den Berg HM, et al. A sudden increase in factor VIII inhibitor development in multitransfused hemophilia A patients in the Netherlands. <i>Blood<\/i>. 1993;81:2180-2186.","DOI":"10.1182\/blood.V81.8.2180.2180"},{"key":"E00027","unstructured":"Giles AR, Verbruggen B, Rivard GE, Teitel J, Walker I. A detailed comparison of the performance of the standard versus the Nijmegen modification of the Bethesda assay in detecting factor VIII:C inhibitors in the haemophilia A population of Canada. Association of Hemophilia Centre Directors of Canada. Factor VIII\/IX Subcommittee of Scientific and Standardization Committee of International Society on Thrombosis and Haemostasis. <i>Thromb Haemost<\/i>. 1998;79:872-875."}],"container-title":["International Journal of Hematology"],"original-title":[],"link":[{"URL":"http:\/\/www.springerlink.com\/index\/pdf\/10.1532\/IJH97.06019","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,27]],"date-time":"2020-04-27T07:47:14Z","timestamp":1587973634000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1532\/IJH97.06019"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,8,1]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2006,8,1]]}},"alternative-id":["W7T60X45443G7301"],"URL":"https:\/\/doi.org\/10.1532\/ijh97.06019","relation":{},"ISSN":["0925-5710"],"issn-type":[{"value":"0925-5710","type":"print"}],"subject":[],"published":{"date-parts":[[2006,8,1]]}}}